BioCentury
ARTICLE | Clinical News

RSLV-132: Phase II started

August 11, 2014 7:00 AM UTC

Resolve began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate weekly 0.3-10 mg/kg IV RSLV-132 for 4 weeks in about 32 SLE patients. In February 2013, Resolve grant...